AI Article Synopsis
- Multiple sclerosis (MS) disability is linked to three main issues: problems with remyelination, ongoing inflammation from microglia, and neurodegeneration.
- Research aims to uncover how these mechanisms work together and develop advanced imaging techniques to study them in living subjects.
- Current clinical trials are exploring treatments focused on remyelination, protecting nerves, and managing inflammation, but there’s still a need for better methods and clear objectives in these studies.
Article Abstract
"Multiple sclerosis: what therapeutic perspectives? Three phenomena, which may be interrelated, are at the origin of the accumulation of disability in multiple sclerosis: remyelination defect, persistence of chronic microglial inflammation and neuro¬degeneration. Identifying the molecular and cellular mechanisms and being able to follow them in vivo by advanced imaging repre¬sent a major research challenge for the coming years. Several translational pharmacological avenues have already led to clinical trials targeting remyelination, neuroprotection and control of mi¬croglial activation; however, an optimized methodology with rele¬vant endpoints remains to be defined."
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!